For type 2 diabetes mellitus. ANDA 201991, held by Adaptis. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 201991 (Metformin Hydrochloride), held by Adaptis, was first approved by FDA on Jan 18, 2012, with 1 approved supplement and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 18, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jan 18, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters